Ovarian cancer/Fallopian Tube cancer/Primary Peritoneal cancer: Useful in certain circumstances...Pembrozilumab (for microsatellite instability-high [MSI-H] or mismatch repair-deficient [dMMR] solid tumors, or patients with tumor mutational burden-high [TMB-H] tumors ≥10 mutations/ megabase and no satisfactory alternative treatment options).

KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated:...for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.

Here we presented an ovarian cancer case with multiple gene mutations and high TMB, who benefited from a short-term treatment of pembrolizumab and experienced a long-lasting complete response of 2 years till now. The patient was irradiated in the pelvic before pembrolizumab.